When can Elacestrant be purchased in China?

As ofJune 2025,Elacestrant(Elacestrant) has not been officially approved by the State Food and Drug Administration in mainland China, nor has it been included in the National Reimbursement Drug List. This means that the drug is temporarily unavailable through the domestic hospital prescription system and does not fall within the scope of conventional reimbursable drugs in public medical institutions. However, as the global demand for oral SERD drugs for the treatment of breast cancer continues to grow, more and more domestic patients are paying attention to the clinical application prospects of elastran, a new type of endocrine therapy.

Currently, some cross-border medical service platforms, overseas pharmacies and international hospitals can provide access to irastrast. Common versions include:1) The US original version of Orserdu (produced by Menarini), which is used for eligible patients with ESR1 mutated advanced breast cancer; 2) the Lao version of the generic drug, which is basically the same as the original drug in terms of ingredients, dosage and packaging, but the price is relatively lower, and is mainly used in overseas markets. These drugs can be purchased through formal third-party international medical cooperation institutions, but patients must provide medical records and be evaluated by a doctor before a prescription can be issued.

Although it has not yet been listed in China, it is understood that Menarini is already promoting elastran's Asian registration strategy and is expected to apply for listing in China in the next few years. If it can successfully pass the review, it is not ruled out that the drug will first enter the self-pay market or be used early through clinical trials, and then participate in medical insurance negotiations for reimbursement.

Currently, if Chinese patients urgently need to use elastran , they should first have an oncologist determine whether their condition is suitable for the drug and determine whether there is an ESR1 mutation as a prerequisite for the indication. Patients should avoid purchasing drugs through unknown channels to prevent counterfeit drugs or illegal products from causing medication risks. If it can be officially launched in China in the future, it will greatly facilitate patients' access to this type of innovative therapy, especially for people with recurrent breast cancer who have failed anti-hormone therapy.

Reference materials：https://www.drugs.com/mtm/elacestrant.html